Medicilon Biology Capabilities

The Biology Platform Builder for Innovation
Medicilon Biology offers a comprehensive biology platform to accelerate drug discovery and development. With over two decades of R&D experience, a vast team of expert scientists, and expansive lab infrastructure, Medicilon supports pharmaceutical innovation from early discovery to translational science.

At the heart of our biology services is a commitment to excellence, scalability, and speed, delivered through state-of-the-art technologies and a client-focused approach.

Core Functions Driving Biology Capabilities

Medicilon’s Biology is powered by four central functional units, providing an integrated system that supports entire drug discovery process as well as mechanism-of-action related studies.

In vitro Biology
Recombinant Protein Expression
Antibody & Biologics Discovery
Structural Biology

Technology & Instrumentation

We uphold excellence, scalability, and speed in every engagement, powered by state-of-the-art technologies and a client-first mindset.

Biacore 8K™ SPR
HTRF/AlphaLISA/Reporter cell
Single Cell Analysis Systems (Rhapsody-BD, SH800-Sony)
NanoString Pro
AKTA Pure (GE) & LC-20ADXR (Shimadzu)
Automatic Liquid Handler (Bravo-Agilent)
BD LSRFortessa™ (20 Channels)

Discover how we accelerate your R&D goals

Protein Science & Engineering

Protein Engineering & Expression Systems

Medicilon provides robust protein engineering services essential for drug target validation and biologics development. We leverage diverse expression systems to ensure optimal protein yield and quality. 

  • Expression in E. coli, baculovirus and mammalian systems
  • Engineering for stability, solubility, and bioactivity
  • Production of enzymes, kinases, and therapeutic proteins
  • Reagent generation (Tool engineered cell lines, protein and antibody labeling and analytics)

Protein Purification & Crystallization

  • Scalable purification (1 mg–500 mg) with >95% purity
  • Tags: His, GST, SUMO, MBP, Flag, Strep
  • Crystallization strategies: soaking, hanging drop, microdialysis

Structure Determination

  • Data collection at APS (USA) and Shanghai Suychrotron
  • Molecular replacement, SeMet labeling, Heavy atom soak

Screening of KRASG12D showcasing optimization of conditions essential for high-quality crystal growth.

X-ray diffraction Data Collection by using synchrotron X-ray sources to obtain high-resolution diffraction patterns, a critical step for accurate structure solution.

KRASG12D crystallization providing insight into the protein’s conformation and GDP-bound state.

KRASG12D-MRTX1133 (target inhibitor) co-crystallization demonstrating binding mode and molecular interactions relevant for drug design.

Assay Platforms & Mechanism Evaluation

Biophysical Assays

Our biophysical assays provide quantitative insights into molecular interactions.

SPR Binding Kinetics
drug-target and protein interactions
Scale-Up Detailed Profiling

 Affinity (KD), IC50/EC50, binding modes

Enzymatic Assays

Medicilon’s extensive enzymatic assay capabilities support small molecule and biologics drug discovery.

- Kinase Panels

150+ validated kinase assays covering diverse families, including assays for specific mutant EGFR and ALK.

- Other Enzyme Assays

Includes panels for PDE family members, proteases, and other functional enzymes via HTRF, ADP-Glo, and AlphaLISA.

- Applications in synthetic lethality, EGFR/ALK inhibitor evaluation.

Cellular Functional Assays

Our comprehensive cell-based functional assays are fundamental for assessing drug efficacy and mechanism of action.

Cell Proliferation/Viability

MTT, CCK8, CTG, MTS, and LDH for cytotoxicity and growth inhibition.

Apoptosis & Necrosis

Quantified via Annexin V staining (FACS) and Caspase 3/7 Glo assays.

Cell Migration & Invasion

Assessed using Transwell assays and Oris™ Cell Migration Assay

Cell Signaling

Evaluated through Western Blotting (WB), HTRF, AlphaLISA, FACS and MSD for phosphorylation, receptor internalization, and pathway activation.

Advanced Systems

Capabilities include 2D and 3D cell culture systems, synergy testing, and drug combination studies.

Specialized Therapeutic Modalities

siRNA/mRNA Drug Platforms

Medicilon is at the forefront of small nucleic acid drug discovery, offering platforms for siRNA and mRNA therapeutics.

  • From sequence design to in vitro & in vivo PK/PD
  • Target validation, off-target screening
PROTAC Evaluation

Our specialized platforms support the discovery and evaluation of PROTAC and Molecular Glue drugs.

  • Cell-free assays including Binary/ternary complex formation assay
  • Different formats of Cellular degradation assays
ADC Evaluation

A comprehensive in vitro assay platform for ADC evaluation, spanning target selection, trafficking, and safety, built on a library of over 300 cancer cell lines.

  • Payloads: MMAE, DM1, DXd
  • Linkers: cleavable/non-cleavable 
  • Functional assays: Binding, Internalization (FACS, Image, IncuCyte), Cytotoxicity/ Bystander effect, cytokine release (Luminex), MOA-related assays

Specialized Target Class Assays

GPCR/Signaling Pathways

Our biophysical assays provide quantitative insights into molecular interactions.

Our specialized GPCR platform provides in-depth functional analysis of G protein-coupled receptors and related signaling pathways.

  • Activation studies for GLP1, GIP, GCGR
  • Methods: cAMP, Ca²⁺ signaling and HTRF
GPCR/Signaling Pathways

cAMP release in GLP1R and GCGR-expressing cells

A: Glucagon induced cAMP release in HEK293/Ga15/GCGR were tested through TR-FRET assay

B: Trizepatide induced cAMP release in HEK293/GIPR were tested through TR-FRET assay

C: Compound induced cAMP release in CHO-K1/GLP2R/Gα15 were tested through TR-FRET assay

Immune Cell Function & Immunotherapy

Medicilon’s advanced immune cell analysis platform supports immunotherapy, vaccine development, and basic immunological research:

  • CAR-T, TCR-T, NK, TIL phenotyping and functional testing
  • Cytokine release (MSD, Luminex), T/B cell activation and proliferation, ADCC/CDC

Multiplex MSD analysis of serum cytokine/chemokine levels in cynomolgus monkeys (n=6/group) at 0, 6, and 24 h post subcutaneous dosing (1 mg/kg) with control or test article. Measured markers include INF-γ, IL-10, IL-1β, IL-6, IL-8, MIP-1α, MIP-1β, IL-12P40, G-CSF, and IL-12P70. Elevated cytokines at 6 h in the test group (red bars) indicate an acute immune response.

Human PBMCs were incubated with antibody or ADCs, cytokine released in supernatant were tested through Luminex

MSD multiplex assays panels 

Antibody & Biologics Discovery Platforms

Medicilon offers a robust and integrated suite of platforms for antibody and biologics discovery, supporting projects from early discovery to IND.

Discovery Platforms
  • Hybridoma Platform
  • Phage Display Platform
  • Single B-cell Sequencing Platform
  • mRNA Display
Humanization & Optimization
  • From animal immunization to antibody sequencing
  • Analytical workflows for PK/PD, toxicity, and MoA

NanoString & High-Throughput Transcriptomics

Multi-Omics, Data Analysis & Translational Research

Medicilon employs advanced multi-omics technologies to provide deep biological insights. 

NanoString nCounter Pro
  • Amplification-free, highly multiplexed mRNA quantification
  • 29 panels in oncology, immunology, infectious disease, neuroscience
Functional Assay Portfolio
  • Cytokine profiling
  • Signaling Assays (cAMP/cGMP release assays, IP3 release, Calcium release)
  • Phosphorylation
  • RNA-seq
  • Luminex, MSD, and ELISA-based high-throughput formats
Data Reporting
  • Heatmaps
  • Volcano plots
  • Custom bioinformatic dashboards

At A Glance: Antibody & Biologics Discovery Platforms

Medicilon’s integrated biology and in vitro pharmacology platforms provide an end-to-end solution for drug discovery and preclinical research.

Capability
Core Output
Use Case
Recombinant protein reagents
Assays, structural biology
SPR, enzymatic, 2D/3D cell-based models
MoA & pharmacology
Mechanism evaluation
Drug validation
Antibodies, nanobodies, peptide ligands
Biologics lead generation
Functional signaling, immunotherapy
Immune oncology, metabolic disorders
Transcriptomics, bioinformatic insights
Translational research

FAQs

Have more questions? Reach out to our experts.

Medicilon provides a comprehensive suite of in vitro biology assay services to support drug discovery and preclinical research. Our team offers high-throughput and customized platforms designed to generate accurate, reproducible, and regulatory-compliant data. Available assays include:

  • Enzyme activity and inhibition panels for drug target validation
  • Cell proliferation, migration, and viability assays for therapeutic efficacy testing
  • Immunological assays (ELISA, cytokine release, flow cytometry) to evaluate immune responses
  • GPCR and ion channel functional assays for receptor signaling studies
  • 2D/3D cell culture models that closely mimic human physiology for advanced drug screening

By combining industry-leading instrumentation with expert assay development, Medicilon ensures reliable results that accelerate early-stage drug discovery. Our in vitro biology services are tailored to meet specific project requirements and can be scaled for both exploratory research and regulatory submissions.

At Medicilon, recombinant protein expression and purification services are designed to support diverse applications, including structural biology, antibody discovery, and drug screening. We offer multiple expression systems to optimize yield and bioactivity:

  • E. coli expression for rapid, cost-effective protein production
  • Baculovirus/insect cell systems for post-translational modifications
  • Mammalian cell expression for complex and glycosylated proteins

Each project includes:

  • Scalable upstream expression and downstream purification protocols
  • Quality control assays to confirm protein stability, folding, and bioactivity
  • Delivery of proteins suitable for structural studies, functional assays, and antibody generation

With flexibility across expression platforms and expertise in purification workflows, Medicilon ensures proteins are produced with the highest integrity for your specific research needs.

Yes. Medicilon offers end-to-end antibody and biologics discovery services, supporting every stage from hit generation through preclinical development. Our integrated solutions include:

  • Antibody screening via hybridoma, phage display, or mRNA display technologies
  • Affinity maturation and humanization to improve therapeutic potential
  • Biophysical and biochemical characterization, including immunogenicity, PK/PD, and stability studies
  • Toxicity and safety assessments aligned with regulatory requirements

By combining advanced platforms with scientific expertise, Medicilon enables rapid identification and optimization of biologics. Our comprehensive workflows ensure that antibodies and therapeutic proteins are thoroughly characterized, derisking development and accelerating timelines from early discovery through IND-enabling studies.

Medicilon’s structural biology services help researchers gain insights into drug-target interactions, enabling rational drug design and optimization. Capabilities include:

  • Protein crystallization and X-ray diffraction for high-resolution structural data
  • Cryo-electron microscopy (Cryo-EM) sample preparation and imaging for large or complex proteins
  • Ligand docking and structure-based drug design to accelerate hit-to-lead development
  • Membrane protein structural analysis, a key challenge in drug discovery

Our structural biology experts collaborate closely with drug discovery teams to elucidate molecular mechanisms and optimize compounds. By integrating structural insights with medicinal chemistry and bioinformatics, Medicilon enables efficient structure-guided drug design for both small molecules and biologics.

Yes. Medicilon offers custom bioanalytical method development and validation tailored to unique project requirements. Our services include:

  • Tailored assay design and optimization for specific analytes or biomarkers
  • Multiple formats such as ELISA, LC-MS/MS, HTRF, and SPR for flexibility in analysis
  • Regulatory-aligned QC benchmarks that ensure data reproducibility and compliance

Whether your project requires PK/PD studies, immunogenicity testing, or biomarker quantification, Medicilon provides scalable and customized solutions. Our bioanalytical team ensures methods are validated to meet regulatory expectations, enabling smooth progression into preclinical and clinical development stages.

Yes. Medicilon offers custom bioanalytical method development and validation tailored to unique project requirements. Our services include:

  • Tailored assay design and optimization for specific analytes or biomarkers
  • Multiple formats such as ELISA, LC-MS/MS, HTRF, and SPR for flexibility in analysis
  • Regulatory-aligned QC benchmarks that ensure data reproducibility and compliance

Whether your project requires PK/PD studies, immunogenicity testing, or biomarker quantification, Medicilon provides scalable and customized solutions. Our bioanalytical team ensures methods are validated to meet regulatory expectations, enabling smooth progression into preclinical and clinical development stages.

Yes. Medicilon provides custom antibody and reagent development services to support drug discovery and diagnostic applications. Our offerings include:

  • Polyclonal and monoclonal antibody generation tailored to specific targets
  • Peptide synthesis and recombinant protein production for immunogen design
  • Labeling, conjugation, and assay-ready formats for immediate use in screening

By combining advanced production technologies with rigorous quality control, Medicilon ensures that custom antibodies and reagents meet high-performance standards. These solutions can be applied in assay development, biomarker research, and therapeutic discovery, offering flexibility for diverse research goals.

Yes. Medicilon offers custom bioanalytical method development and validation tailored to unique project requirements. Our services include:

  • Tailored assay design and optimization for specific analytes or biomarkers
  • Multiple formats such as ELISA, LC-MS/MS, HTRF, and SPR for flexibility in analysis
  • Regulatory-aligned QC benchmarks that ensure data reproducibility and compliance

Whether your project requires PK/PD studies, immunogenicity testing, or biomarker quantification, Medicilon provides scalable and customized solutions. Our bioanalytical team ensures methods are validated to meet regulatory expectations, enabling smooth progression into preclinical and clinical development stages.

Medicilon’s biology labs are equipped with advanced instrumentation and technology platforms that enable precision, scalability, and reproducibility. Available tools include:

  • Surface Plasmon Resonance (SPR) for binding affinity analysis
  • Homogeneous Time-Resolved Fluorescence (HTRF) for high-throughput screening
  • LC-MS/MS mass spectrometry for bioanalytical studies
  • Automated cell imaging systems and multiplex assay platforms for enhanced efficiency

By combining cutting-edge tools with expert staff, Medicilon delivers reliable results that accelerate decision-making in drug discovery and development.

Yes. Medicilon offers multi-omics and bioinformatics services to provide a holistic view of biological mechanisms and therapeutic potential. Our capabilities include:

  • Transcriptomics, proteomics, and metabolomics profiling for comprehensive biological insights
  • Advanced bioinformatics pipelines for biomarker discovery and pathway analysis
  • Data integration with preclinical and clinical datasets to inform drug development

By combining multi-omics data with computational biology, Medicilon helps researchers uncover disease mechanisms, identify biomarkers, and optimize therapeutic strategies. This integrated approach ensures data-driven decisions that enhance drug discovery and translational research.

Let’s Build Your Next Breakthrough - Together

Get expert input in biology, assay development, and functional validation.

Contact Medicilon

Name
Address

Search Medicilon

Medicilon Empowers Strategic Partner SAPU to Obtain Clinical Trial Approval for Sapu003 in Australia

Medicilon Receives International Accreditation Again! Successfully Obtains OECD GLP Certificate

【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development